Mechanism of an Inhibitory Effect of nipradilol on Rat Vascular Smooth Muscle Cell Growth.

IGARASHI M; HIRATA A; YAMAGUCHI H; SUGAE N; KADOMOTO Y; JIMBU Y; DAIMON M; KATO T; TOMINAGA M

Art

J-GLOBAL ID：200902244324757854 Reference number：03A0727735

Mechanism of an Inhibitory Effect of nipradilol on Rat Vascular Smooth Muscle Cell Growth.

ラット血管平滑筋細胞の増殖に対するニプラジロールの阻害作用のメカニズム

Publisher site Copy service {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=03A0727735&COPY=1") }}
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=03A0727735&from=J-GLOBAL&jstjournalNo=L2187A") }}

Author (9)： , , , , , , , ,
Material：
Volume： 10 Issue： 4 Page： 226-233 Publication year： Aug. 31, 2003
JST Material Number： L2187A ISSN： 1340-3478 CODEN： JATHEH Document type： Article
Article type：原著論文 Country of issue： Japan (JPN) Language： ENGLISH (EN)

,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=03A0727735&from=J-GLOBAL&jstjournalNo=L2187A") }}

Vasculature , Basic medicine on cardiovascular system

Reference (35)：

(1) Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, De Leeuw PW, Dolley CT, Fletcher AE, Forette AE, Leonetti G, Nachev C, O’Breien ET, Rosenfeld J, Rodicio JL, Toumilehto J, and Zanchetti A: Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: The Systolic Hypertension in Europe (Sys-Eur) Trial Investigators. Lancet, 350: 757−764, 1997
(2) Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, and Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet, 351: 1755−1762, 1998
(3) Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, and Wagner EH: Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA, 282: 786−790, 1999
(4) Sacco RL, Wolf PA, and Gorelick PB: Risk factors and their management for stroke prevention: Outlook for 1999 and beyond. Neurology, 53: S15−S24, 1999
(5) Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, and Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation, 102: 1503−1510, 2000

ｍore...

, , , , ,

Return to Previous Page